This page shows the latest NVX-CoV2373 news and features for those working in and with pharma, biotech and healthcare.
Novavax has announced topline results from a phase 3 trial of its COVID-19 vaccines, showing that its Omicron-adapted BA.1 vaccine candidate, NVX-CoV2515, met the primary strain-change ... The trial included the company's bivalent vaccine, the
Novavax’s COVID-19 vaccine, Adjuvanted (NVX-CoV2373) has been granted emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) as a booster in adults 18 years and
New data from a trial conducted in the US and Mexico has showed that Novavax’s COVID-19 vaccine NVX-CoV2373 is 90% effective at preventing COVID-19. ... PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile.
Previously, Novavax’s chief executive officer Stanley Erck said that the company was aiming for a US Food and Drug Administration (FDA) emergency approval of its vaccine – NVX-CoV2373 – as early ... Peak capacity for the vaccine is expected in the
Earlier this year, reports emerged that Novavax has encountered issues with sourcing some raw materials used in the manufacturing process for NVX-CoV2373. ... The UK government has already signed an advanced purchase agreement with Novavax for 60 million
GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. ... The UK government signed an advanced purchase agreement with Novavax in August 2020 for 60 million doses of
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...